Ann: Update on Phase I/II Clinical Trial for Burn Wound Infection, page-58

This as far as I can tell is first proof of efficacy and safety in humans of a completely new type of anti biotic that does not promote anti biotic resistance.
At this stage it has shown that the originally proposed 2 week protocol for testing has proven to be too long. It appears even the worst infections it has been tested against including multi drug resistant strains and biofilms have all been "cured" within a mere 7 days.
It seems to me this is company making in that assuming there is no change as this trial progresses they now have a drug that should be able to go through Phase 3 trial and so far has been shown to "cure" chronic infections. They then have access to FDA approval via the fast track approval granted there.

To me a few weeks ago we were another company with a medication in trials that had potential, but as many have pointed out only a small percentage make it through to market.
Now it appears we have de risked this to a huge degree, and in doing so we have a product that has global significance regardless of how the iv sepsis trial now fares.

I guess whatever happens you will always hold a grudge with this company for whatever happened in the past as is your prerogative. All I can say is I had a little doubt building as trial progressed with no updates, but having now heard the word Cure from those involved, and knowing this is a highly regarded completely independent hospital, I'm happy to hold as long as it takes.

180 million mc for a company at this point in its progression is almost comical. Imagine if they could bring out an announcement that the anti viral works equally against all covid variants?

sorry my mistake. Mc currently only 161 million with 174 ish million shares on issue and not sure how many millions still in bank. Unbelievable position to be in and a gift with this result.